Bayer HealthCare announced that it has opened a new, expanded facility for the Interventional franchise within its Medical Care’s Radiology and Interventional business located at its Coon Rapids headquarters site.
Read More

MEDRAD, INC. today unveiled industry-first interoperability with the release of the company’s Certegra Informatics Connect.RIS application.
Read More

Bayer HealthCare’s affiliate MEDRAD, INC. today announced that 5 year data from the THUNDER trial demonstrated a 59% relative reduction in target lesion revascularization rates in popliteal arteries of patients with peripheral arterial disease.
Read More

MEDRAD Interventional announced today that five-year data from the THUNDER trial will be presented at the 2011 Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation, in San Francisco.
Read More

Pathway Medical Technologies, Inc., a wholly owned subsidiary of MEDRAD, Inc., announced initiation of the JET Registry, a registry focused on tracking patients with symptomatic peripheral arterial disease (PAD) undergoing percutaneous interventions.
Read More

MEDRAD has acquired Pathway Medical Technologies of Kirkland, Washington. Pathway is a leader in mechanical atherectomy in the field of vascular intervention.
Read More

MEDRAD announced it has received CE Mark for its Cotavance™ Paclitaxel Coated Balloon Angioplasty Catheter with Paccocath® technology.
Read More

MEDRAD, INC. announced that Jack Darby has joined the company as vice president of MEDRAD Interventional.
Read More

MEDRAD, a market leader in computed tomography, magnetic resonance imaging and interventional cardiology, learned today that it will receive a 2010 Baldrige Award for excellence in manufacturing—an honor that it first received in 2003.
Read More